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Objective: This study was performed to evaluate the potential clinical value of concurrent chemotherapy and pulsed high 
intensity focused ultrasound (HIFU) therapy (CCHT), as well as the safety of pulsed HIFU, for the treatment of unresectable 
pancreatic cancer.
Materials and Methods: Twelve patients were treated with HIFU from October 2008 to May 2010, and three of them 
underwent CCHT as the main treatment (the CCHT group). The overall survival (OS), the time to tumor progression (TTP), 
the complications and the current performance status in the CCHT and non-CCHT groups were analyzed. Nine patients in 
the non-CCHT group were evaluated to determine why CCHT could not be performed more than twice. 
Results: The OS of the three patients in the CCHT group was 26.0, 21.6 and 10.8 months, respectively, from the time of 
diagnosis. Two of them were alive at the time of preparing this manuscript with an excellent performance status, and one 
of them underwent a surgical resection one year after the initiation of CCHT. The TTP of the three patients in the CCHT 
group was 13.4, 11.5 and 9.9 months, respectively. The median OS and TTP of the non-CCHT group were 10.3 months and 
4.4 months, respectively. The main reasons why the nine patients of the non-CCHT group failed to undergo CCHT more than 
twice were as follows: pancreatitis (n = 1), intolerance of the pain during treatment (n = 4), palliative use of HIFU for pain 
relief (n = 1) and a poor physical condition due to disease progression (n = 3). No major complications were encountered 
except one case of pancreatitis. 
Conclusion: This study shows that CCHT is a potentially effective and safe modality for the treatment of unresectable 
pancreatic cancer. 
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INTRODUCTION
Pancreatic cancer has a dismal prognosis, and most 
cases of pancreatic cancer are unresectable at the time of 
diagnosis because pancreatic cancer tends to involve the 
major vital vessels even in the early stages. Therefore, many 
pancreatic cancer patients have no choice other than to 
depend on chemotherapy, even when there is no evidence of 
distant metastasis at the time of diagnosis. In this regard, 
many studies have focused on developing more effective 
chemotherapeutic drugs and enhancing drug delivery to 
the cancers, or they have examined the effects of adding Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 177
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SMA infarction, occurred after treatment with this type of 
HIFU machine (8, 9). However, such side effects should be 
avoided in patients with unresectable pancreatic cancers 
for the following reasons: they can destroy the quality of 
the remaining life, they can postpone chemotherapy, which 
is vital in these patients, and they can impair the patient’s 
performance status. Indeed, a good performance status is 
known to be signifi  cantly associated with the median OS of 
pancreatic cancer patients (4). 
Researchers have recently begun to focus more on 
pulsed HIFU therapy with low energy because animal and 
human research has indicated its potential to enhance 
the chemotherapeutic effect (10-13). In addition, pulsed 
HIFU with low energy employs much lower acoustic energy 
intensities (< 3 kW/cm
2) than continuous HIFU, and 
exposure to these levels does not require hospitalization or 
general anesthesia and it has a low complication rate (13, 
14). Accordingly, pulsed HIFU with a low energy appears 
to be a more reasonable, safer option for patients with 
unresectable pancreatic cancer because it allows patients 
locoregional therapy. 
High intensity focused ultrasound (HIFU) has emerged 
in recent years as a new noninvasive treatment for solid 
malignant tumors, including pancreatic cancer (1). An early 
clinical study concluded that HIFU was safe and feasible 
for the treatment of advanced pancreatic cancer with a 
median overall survival (OS) of 11.25 months (range: 2-17 
months) (2). Their results suggested that HIFU offers 
survival benefi  ts given that the median OSs of gemcitabine 
and of gemcitabine-capecitabine chemotherapies are 6-10 
months for patients with advanced pancreatic cancer (3-6). 
However, they treated patients using a continuous (not 
pulsed) HIFU machine with a very high acoustic intensity 
of 5-20 kW/cm
2, which required general anesthesia or 
spinal anesthesia because these intensities delivered as a 
continuous beam cause intolerable pain and severe injury 
to the adjacent organs due to subtle target movement 
(2, 7). Some reports have found that skin burns and pain 
in the treated regions were common and that severe 
complications, such as gastrointestinal perforation and 
Table 1. Summary of Patients Treated with High Intensity Focused Ultrasound
Patient 
No.
Gender/ 
Age
Location Size (cm)
TNM Staging 
at Diagnosis
Stage
Diagnosis 
Method
Pathology
No. of 
HIFU 
Treatment
No. of 
Concurrent 
Treatments
Overall 
Survival 
(Months)
TTP 
(Months)
Current 
Status
CCHT 1 M/60 Uncinate 2.7 T4N0M0 III Biopsy Atypical  cell 18 15 21.6 11.5 Alive
group
2 M/53 Head 3.3 T3N1M1 IV Operation
P/D 
adenocarcinoma
10 7 26.0 13.4 Alive
3 M/61 Head 4.6 T4N1Mx
III or 
IV
Imaging 8 8 10.8 9.9 Dead
Non- 4 M/35 Body 3.5 T4N1M0 III Biopsy Atypical  cell  5 2 12.4 4.4 Dead
CCHT 5 M/73 Body 2.4 T4N1M0 III Imaging 3 1 06.3 2.4 Dead
group 6 F/72 Body 2.3 T4N0M0 III Aspiration Atypical cell 2 2 10.3 5.8 Dead
7 F/45 Head 3.9 T4N1M1 IV Biopsy
P/D 
adenocarcinoma
21 05.5 1.9 Dead
8 M/67 Head 2.4 T4N0M1 IV Biopsy
M/D 
adenocarcinoma
2 0 42.5 36.8 Dead
9 M/47 Head 5.6 T4N1M1 IV Imaging 2 0 07.3 2.4 Dead
10 F/71 Head 3.6 T4N0M0 III Biopsy Adenocarcinoma 1 1 17.2 10.7 Dead
11 M/76 Head 5.2 T4N0M1 IV Biopsy
Squamous cell 
carcinoma
10 02.1 1.0 Dead
12 F/65 Body 2.9 T4N0M0 III Aspiration Adenocarcinoma 1 0 22.1 17.5 Dead
Median 
(95% CI)
3.5 
(2.3-5.3)
10.3 
(1.4-19.3)
4.4 
(0.0-9.0)
Note.— CCHT = concurrent chemotherapy and pulsed high intensity focused ultrasound therapy, CI = confi  dence interval, Current 
status = patient’s status at time of writing, HIFU = high intensity focused ultrasound, M/D = moderately differentiated, 
No. = number, P/D = poorly differentiated, TNM = tumor, node, metastasis, TTP = time to tumor progressionKorean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 178
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to maintain staying on routine chemotherapy and have a 
normal life, and it offers the opportunity of achieving some 
benefi  t by enhancing the effect of chemotherapy.
Twelve patients were treated with pulsed HIFU with low 
energy from October 2008 to May 2010. In particular, three 
patients underwent concurrent chemotherapy and pulsed 
HIFU therapy (CCHT) with low energy. This study evaluated 
the potential clinical value of CCHT and the safety of 
pulsed HIFU for the treatment of unresectable pancreatic 
cancer, and here we summarize our experiences before we 
commence conducting a large prospective study. 
MATERIALS AND METHODS
Patients 
Institutional Review Board approval was obtained for this 
retrospective study, and informed consent was waived due 
to the retrospective nature of this study.   
Twelve patients were treated with HIFU from October 
2008 to May 2010. Table 1 summarizes the patients’ 
data. The 12 patients were determined to be eligible 
for HIFU treatment by using the following criteria: they 
had a diagnosis of pancreatic cancer as confi  rmed by the 
pathologic fi  ndings or by the clinical and imaging fi  ndings 
typical of pancreatic cancer, the tumor was unresectable 
based on the guidelines of the 6th edition of the American 
Joint Committee on Cancer (AJCC), the lesion was mainly 
located in the pancreatic head or body and they had a 
Karnofsky performance status scale rating of at least 70%.
The following inclusion criteria were used to examine the 
effect of CCHT: 1) the patients underwent at least three 
sessions of concurrent treatments, which were defi  ned 
as HIFU within 24 hours of a gemcitabine injection, 2) 
initiation of the fi  rst CCHT was done within three months 
of the diagnosis to meet the requirements that concurrent 
treatment should be the main treatment and 3) there was 
no history of radiation or cyberknife treatment before and 
after CCHT. Three of the 12 patients satisfi  ed these criteria 
and they were categorized into the “CCHT group.” The other 
nine patients were categorized into the “non-CCHT group.” 
The High Intensity Focused Ultrasound Device
A FEP-BY
TM HIFU unit (Yuande Biomedical Engineering 
Limited Corporation, Beijing, China) was used throughout 
this study (14). The HIFU treatment was performed using 
an upper HIFU transducer enveloped in a degassed water 
bladder with the patient lying supine on the treatment table. 
The targeted pancreatic tumor was identifi  ed using a B-mode 
ultrasound imaging transducer (GE Logiq 5, Seongnam, 
Republic of Korea) before the HIFU treatment. The HIFU 
beam was insonated into the body and moved automatically 
from spot to spot in an overlapping manner to treat a 
volume of tissue. Local or general anesthesia was not needed 
in any of the patients. The patients were fasted for nine 
hours before the HIFU treatment. The treatment parameters 
were input target energy: 500-1000 J/spot, input acoustic 
intensity (spatial average-temporal average intensity, Isata): 
1-2 kW/cm
2, pulses/spot: 50-70, transit time of a unit 
pulse (t1): 150 ms and intermission time between pulses 
(t2): 150 ms, intermission time between spots: 5 sec (duty 
cycle: 50%, pulse repetition frequency: 3.3 Hz, sonication 
duration: 15-21 sec). The acoustic power was adjusted with 
Table 2. Summary of Patients Treated with Concurrent Chemotherapy and High Intensity Focused Ultrasound 
Treatment 
Patient 
No.
Gender/
Age
Diameter of 
Primary Tumor 
(cm)
Mean 
Target 
Energy/
Spot
Mean 
Acoustic 
Intensity 
(Isata)
Mean 
Ablation 
Time/
Session
No. of Sessions 
with 
Skin Burn
No. of 
Sessions with 
Pain during 
Treatment
No. of 
Sessions 
Using 
Analgesics
No. of 
Severe 
Complications
Current 
KPS Score
1 M/60 2.7 752.7 J
1.4 
kW/cm
2
62.3 
minutes
1 
(grade 1)
3 6 0 90%
2 M/53 3.3 745.1 J
1.4 
kW/cm
2
54.6 
minutes
1 
(grade 1)
8 7 0 90%
3 M/61 4.6 844.0 J
1.7 
kW/cm
2
79.7 
minutes
1 
(grade 2)
1 
(grade 1)
3 4 0 Dead
Note.— CCHT = concurrent chemotherapy and high intensity focused ultrasound therapy, Isata = spatial average temporal average 
intensity, KPS = Karnofsky performance score, No. = number, TTP = time to tumor progressionKorean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 179
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respect to the tumor depth and the subcutaneous tissue 
thickness, as measured by ultrasound imaging, to achieve 
the required in situ energy dose (15). To avoid skin burns, a 
cold ultrasound coupling gel was applied frequently between 
the water bladder and skin during the procedure. 
AB
CD
Fig. 1. 60-year-old man with unresectable pancreatic cancer arising from uncinate process and encasing superior mesenteric 
artery. 
A. Contrast-enhanced CT image (January 8, 2009) taken before start of concurrent chemotherapy and high intensity focused ultrasound therapy 
shows infi  ltrative soft tissue tumor (arrowheads) arising from uncinate process of pancreas with upward and downward encasement of superior 
mesenteric artery (arrows). 
B. Contrast-enhanced CT image (February 20, 2009) taken after three consecutive concurrent chemotherapy and high intensity focused ultrasound 
therapy sessions shows slight interval decrease in tumor size and tumor soft tissue attenuation (arrowheads) around superior mesenteric artery 
(arrows). 
C. Contrast-enhanced CT image (July 14, 2009) taken after additional three sessions of concurrent chemotherapy and high intensity focused 
ultrasound therapy shows another interval decrease in tumor size and amount of soft tumor tissue (arrowheads) encasing superior mesenteric 
artery (arrows). 
D. PET-CT image (December 29, 2009) shows hot uptake (arrows) in left paraaortic area at level of superior mesenteric artery take-off. Left 
paraaortic area had not previously been treated with high intensity focused ultrasound because no mass was observed in this area on prior CT 
images. Note that treated soft tissue (arrowheads) around superior mesenteric artery does not show any signifi  cant uptake. Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 180
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Concurrent Treatment Protocol
Gemcitabine (2,2-difl  uorodeoxycytidine, Gemzar; Eli 
Lilly & Co., New York, NY) 1000 mg/m
2 was administered 
as a 30 minute intravenous infusion weekly for three 
weeks followed by a one week rest period. Chemotherapy 
was omitted according to the physician’s decision if a 
signifi  cant hematologic or nonhematologic toxicity had 
not recovered on the day of therapy. Within 24 hours of 
infusing gemcitabine, the HIFU treatment was conducted 
using the protocol described above. HIFU was generally 
cancelled when chemotherapy was cancelled due to an 
adverse reaction. However, the HIFU treatment alone was 
occasionally performed in cases with a long absence of 
treatment. Gemcitabine administration was continued until 
disease progression occurred.
Assessment
Regarding the three patients in the CCHT group, the 
following were analyzed: the number of CCHT sessions, 
the number of HIFU alone treatments, the mean target 
energy per spot (J/spot), the mean input acoustic intensity 
(W/cm
2), the mean treatment time from the fi  rst to last 
sonication, the serial changes in the level of the tumor 
marker CA 19-9, the serial changes of the tumor size by 
CT, the PET-CT fi  ndings if available, the OS from the time 
of diagnosis, the time to tumor progression (TTP), the 
presence of complications (redness, skin burn, treatment-
related pain, pancreatitis, gastrointestinal injury and 
others) and the current performance status as determined 
by the Karnofsky scoring system.
 The OS was calculated from the date of diagnosis to the 
date of death from any cause or the last documented follow-
up. The TTP was calculated from the start of treatment to 
the date of the fi  rst documented progression or the last 
follow-up.   
Regarding the nine patients in the non-CCHT group, we 
determined the main reason why CCHT was not performed 
more than twice. The OS from the time of diagnosis, the TTP 
and the presence or absence of complications during the 
HIFU treatment were also analyzed.
RESULTS
The Concurrent Chemotherapy and Pulsed High Intensity 
Focused Ultrasound Therapy Group
Tables 1 and 2 summarize the survival data, the treatment 
protocol and the complications of the CCHT group. Figures 
1-3 show the serial changes in the CA 19-9 levels and the 
CT-determined tumor sizes.
Patient 1 (Fig. 1) (Tables 1, 2) had a 2.7 cm soft tissue 
lesion encasing the superior mesenteric artery (SMA) with 
an indistinct low attenuation area in the uncinate process 
of the pancreas, as seen on CT (Fig. 1A). The laparoscopic 
biopsy revealed atypical ductal cells and this suggested 
pancreatic carcinoma. PET-CT showed increased activity 
around the SMA. After gemcitabine was fi  rst administered 
in January 2009, CCHT was performed since January 2009 
according to the gemcitabine infusion schedule. At the 
end of the fi  rst six sessions of CCHT, the CA 19-9 level had 
decreased from 50.8 U/mL to 21 U/mL. After six sessions of 
CCHT, three consecutive weekly CCHTs were performed with 
a 1-3 month intermission. The tumor size decreased and it 
remained stable in size for approximately one year since the 
fi  rst CCHT (Fig. 1B). However, subsequently, the CA 19-9 
level began to be reelevated to more than 100 U/mL and 
the follow-up PET-CT revealed a small region of hot activity 
E
Fig. 1. 60-year-old man with unresectable pancreatic cancer 
arising from uncinate process and encasing superior mesenteric 
artery. 
E. First plot demonstrates change in CA 19-9 concentration over 
time, showing that CA 19-9 levels were stable for approximately one 
year. Second plot shows change in tumor size (determined by CT) 
over time. After regression of tumor size, there was very slow change 
in size of main mass with time. Third plot shows date and number of 
chemotherapy sessions prior to enrollment and dates of concurrent 
chemotherapy and high intensity focused ultrasound (HIFU) therapy 
(CCHT) or high intensity focused ultrasound alone treatment. Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 181
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at the left paraaortic area that had not been treated with 
CCHT (Fig. 1D). Afterwards, the paraaortic lesion was 
treated with three consecutive sessions of CCHT. The follow-
up CT (March 2010) showed that the attenuation of the left 
paraaortic area was reduced compared to the previous CT. 
On March 18, 2010, a new chemotherapeutic regimen (TS-1 
and CDDP) was attempted due to a continuous increase 
in the CA 19-9 level. However, it was cancelled after 
the fi  rst treatment session due to severe adverse effects. 
Four consecutive sessions of CCHT with gemcitabine were 
performed from April 7, 2010 to April 28, 2010. After this 
treatment, the CA 19-9 level was decreased temporally (1341 
U/mL → 1105 U/mL). Currently, the patient is refusing 
further chemotherapy. In September 2010, at the time 
of preparing this manuscript, he was still alive in a good 
physical condition (Karnofsky performance status scale: 80-
AB
Fig. 2. 53-year-old man with stage IV pancreatic body cancer and liver metastasis.  
A. Contrast-enhanced CT (September 19, 2008) taken before start of concurrent chemotherapy and high intensity focused ultrasound therapy 
shows irregular soft tumor tissue (short white arrows) at pancreatic head with invasion to distal common bile duct. Multiple necrotic nodes (long 
white arrows) are shown in mesentery. Common bile duct contains metallic stent. Small hypodense lesion (black arrow) is present in segment 5, 
indicating metastasis. 
B. Contrast-enhanced CT (May 15, 2009) taken after 4 sessions of concurrent chemotherapy and high intensity focused ultrasound therapy and 3 
sessions of high intensity focused ultrasound therapy alone shows remarkable interval decrease of tumor size (arrows). Necrotic nodes present in 
mesentery were also reduced in size, and liver nodule disappeared (not shown). 
C. Surgical specimen of pancreas after pylorus preserving pancreaticoduodenectomy (November 11, 2009) shows irregular whitish tumor (arrows) 
in pancreatic head. Pathological diagnosis was poorly differentiated adenocarcinoma. 
D. Contrast-enhanced CT (January 9, 2010) taken two months after surgery shows reappearance of liver nodule (short arrows) in segment 5, 
suggesting relapse of liver metastasis. Slightly enlarged portocaval node was also observed (long arrow). 
CDKorean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 182
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90%), and there are no sign of distant metastases. 
Patient 2 (Fig. 2) (Tables 1, 2) was diagnosed with a 
3.3 cm unresectable pancreatic head cancer invading the 
peripancreatic tissue and the distal common bile duct 
with enlarged mesenteric lymph nodes according to the 
CT taken in July 2008. Three days later, drainage of the 
common bile duct was achieved via endoscopic retrograde 
cholangiopancreatography (ERCP) through the insertion 
of an uncovered metallic stent. At that time, the tumor 
was considered to be surgically resectable. However, the 
follow-up CT taken in September 2008 revealed an interval 
increase in the size of the main pancreatic mass (3.3 cm 
→ 4.3 cm) and the mesenteric lymph nodes, and the new 
development of a small liver metastasis in segment 5 of 
the liver (Fig. 2A). Therefore, surgery was cancelled and a 
gemcitabine-capecitabine (Xeloda; F. Hoffmann-La Roche 
AG, Basel, Switzerland) combination was administered. 
The capecitabine was administered orally at a dose of 830 
mg/m
2 twice a day with gemcitabine being given once a 
week for the fi  rst three weeks. However, the capecitabine 
was discontinued due to hand-foot syndrome. CCHT was 
performed from November 2008. After the fi  rst three CCHT 
sessions, the CA 19-9 level decreased to 40.3 U/mL and 
the tumor size according to CT decreased to 2.8 cm in 
diameter (Fig. 2B). The liver nodule observed in segment 
5 had completely disappeared according to the CT taken in 
May 2009. However, the CA 19-9 level was elevated to more 
than 100 U/mL in June 2009 and the CT in August 2009 
revealed a slight interval increase in tumor size (2.5 cm → 
2.9 cm in diameter). Surgical resection was considered given 
the lack of vital vessel involvement by the pancreatic tumor 
and his excellent physical condition (Karnofsky performance 
status scale: 100%). The liver lesion in segment 5 was not 
observed before surgery. After some delay of surgery due to 
cholangitis and a myocardial ischemic attack, the surgical 
resection (pylorus preserving pancreaticoduodenectomy) 
was performed in November 2009 (Fig. 2C). The pathological 
diagnosis was poorly differentiated adenocarcinoma, and 
the surgical staging was T3N1. No peritoneal seeding was 
identifi  ed. However, on a postoperative follow-up CT taken 
in November 2009, a single 1 cm nodule reappeared in 
segment 5 of the liver and it began to increase slowly in 
size, confi  rming that it was a liver metastasis (Fig. 2D). 
In addition, the portocaval lymph node had also increased 
slowly in size. A new chemotherapeutic regimen (TS-1 and 
CDDP) was started from April 2010. Thus far, the patient’s 
Karnofsky performance statue scale is 90-100%, and no 
signs of another distant metastasis have been observed. 
Patient 3 (Fig. 3) (Tables 1, 2) was diagnosed with a 
4.6 cm infi  ltrative unresectable cancer of the pancreatic 
head with invasion of the distal common bile duct and 
encasement of both the celiac axis and the main portal vein 
in August 2008 (Fig. 3A). From the time of the diagnosis, 
there was a small quantity of ascites, which might represent 
peritoneal seeding (Fig. 3B). Therefore, the initial TNM 
staging was T4N1Mx (stage III or IV). In August 2008, 
ERCP was performed with the insertion of an uncovered 
metallic stent for drainage of the common bile duct. From 
August 2008, six sessions of a weekly gemcitabine infusion 
(2 cycles) were performed with capecitabine, which was 
administered orally at a dose of 830 mg/m
2 twice daily for 
three weeks followed by a one week rest period. However, 
the CA 19-9 level increased (140 U/mL → 264 U/mL) and 
no defi  nite change in tumor size occurred according to CT. 
CCHT was started in October 2008. The tumor was partially 
treated during every CCHT session because the upper half 
E
Fig. 2. 53-year-old man with stage IV pancreatic body cancer 
and liver metastasis.  
E. First plot shows change in CA 19-9 concentration with time. CA 
19-9 level was increased again approximately 10 months after initial 
treatment. Second plot shows change of tumor size (determined 
by CT) with time. After initial regression, size of tumor remained 
relatively stable until surgery. Third plot shows dates and number of 
chemotherapy sessions prior to enrollment and dates of concurrent 
chemotherapy and high intensity focused ultrasound (HIFU) therapy 
(CCHT) or high intensity focused ultrasound alone treatment.Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 183
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of the tumor around the celiac axis was always hidden by 
gastric gas on ultrasound. After the fi  rst three consecutive 
sessions of CCHT, the CA 19-9 level decreased (264 U/mL 
→ 177 U/mL) as did the tumor size from 4.6 cm to 3.7 cm 
in diameter (Fig. 3B). The ascites also disappeared (Fig. 
3C). In May 2009, when approximately two months had 
passed after his last CCHT, the CA 19-9 level was found 
to have increased abruptly to 1810 U/mL even though his 
physical performance status was excellent (Karnofsky score, 
90%) and the CT did not reveal any signifi  cant interval 
AB
CD
Fig. 3. 61-year-old man with unresectable pancreatic head cancer with invasion to celiac axis and main portal vein.
A. Contrast-enhanced CT image (August 7, 2008) taken before start of concurrent chemotherapy and high intensity focused ultrasound therapy 
shows irregular bulky mass (white arrows) arising from pancreatic head with invasion to main portal vein and distal common bile duct (black 
arrow). Involvement of common hepatic artery (arrowheads) is shown on right of fi  gure. 
B. Contrast-enhanced CT (November 4, 2008) taken after one session of concurrent chemotherapy and high intensity focused ultrasound therapy 
shows partially interval decrease of attenuation of lower half of tumor (white arrows), which high intensity focused ultrasound could reach. 
Ascites is also shown (black arrow). Tumor infi  ltrations (arrowheads) around common hepatic artery and splenic artery, which high intensity 
focused ultrasound could not reach due to overlying gastric gas, are well shown in right of fi  gure, and they show slight interval increase in 
extent. 
C. Contrast-enhanced CT image (January 28, 2009) taken after additional 5 sessions of concurrent chemotherapy and high intensity focused 
ultrasound therapy shows stable tumor size (arrows) compared to prior CT dated November 4, 2008. Tumor infi  ltration (arrowheads) around 
common hepatic artery and splenic artery is stable in extent. Ascites had disappeared (not shown).  
D. First plot shows change in CA 19-9 concentration with time. CA 19-9 level was stable for approximately eight months. Second plot shows 
change in tumor size (determined by CT) with time. After initial tumor regression, it remained relatively stable until patient succumbed to drug 
induced complications. Third plot shows dates and number of chemotherapy sessions prior to enrollment and dates of concurrent chemotherapy 
and high intensity focused ultrasound (HIFU) therapy (CCHT) or high intensity focused ultrasound alone treatment.Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 184
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change in tumor size at that time. In June 2009, his 
chemotherapeutic regimen was changed to FOLFOX (folinic 
acid [FOL] fl  uorouracil [F] and Oxalipatin [OX]), which 
unfortunately caused severe leucopenia and subsequent 
biliary sepsis (a known severe adverse reaction of the drug). 
Sadly, in July 2009, he succumbed to the biliary sepsis.  
Complications of the Concurrent Chemotherapy and 
Pulsed High Intensity Focused Ultrasound Therapy Group 
Of the 32 CCHTs and six HIFU alone treatments 
administered in the CCHT group, a superfi  cial grade 2 
skin burn occurred in patient 3, and a grade 1 skin burn 
was noted in patients 1, 2 and 3. The grade 2 skin burn 
measured approximately 4 × 5 cm in size and it required 
silver sulfadiazine ointment and a sterile gauze bandage for 
two weeks. It resolved completely within three weeks. The 
two grade 1 skin burns recovered without treatment within 
one week. No major complications such as gastrointestinal 
perforation or pancreatitis were encountered in the CCHT 
group. Mild abdominal pain was reported during treatment 
(during 2 sessions in patient 1, during 6 sessions in patient 
2 and during 2 sessions in patient 3). Moderate abdominal 
pain was noted during one session in patient 1, during 
two sessions in patient 2 and during one session in patient 
3. However, the pain was controlled with Fentanyl, and 
it disappeared immediately after completing the HIFU 
treatment. 
Non-Concurrent Chemotherapy and Pulsed High Intensity 
Focused Ultrasound Therapy Group
The patients in this group did not undergo CCHT more 
than twice for the following reasons: intolerance of pain 
during treatment (n = 4), a poor physical condition due 
to disease progression (n = 3), palliative use of HIFU for 
pain relief (n = 1) and pancreatitis (n = 1). The patient 
who developed pancreatitis after the HIFU treatment had 
a small cystic portion close to the pancreatic cancer before 
treatment, which was probably a pseudocyst. This cystic 
lesion was included in the treatment fi  eld. Two weeks after 
the 3rd HIFU treatment, a large pseudocyst surrounded by 
infl  ammatory changes occurred in the mesentery anterior 
to the pancreas. This complication might have been caused 
by the delayed perforation of the cyst near the pancreatic 
tumor due to damage of the cystic wall by HIFU. All four 
patients in whom the HIFU treatment had been terminated 
due to severe pain during treatment were treated with more 
than 900 J/spot. The use of a high HIFU energy (> 900 
J/spot) was favored for approximately two months after 
initiating HIFU treatment at our center, yet it frequently 
caused severe abdominal pain. Accordingly, the energy 
delivered was lowered to < 800 J/spot, and patients have 
since felt more comfortable during treatment. The patient 
who underwent HIFU for pain palliation did experience 
improvement of their pain (numeric pain scale 7 → 3). 
The median OS and TTP of this group were 10.3 
months (95% confi  dence interval [CI]: 1.4-19.3) and 4.4 
months (95% CI: 0.0-9.0), respectively. A grade 1 skin 
burn occurred in only one of the nine patients, and this 
resolved within one week without any special treatment. 
Subcutaneous sclerosis caused by thermal injury to the 
subcutaneous fat of the anterior abdominal wall occurred 
in two patients, but this occurred after they had been 
administered 1000 J/spot. The sclerosis took four weeks 
to resolve without treatment in one patient. However, in 
the other, it was not completely resolved four months after 
completing the HIFU treatment. 
DISCUSSION
The currently available treatment modalities for the 
management of patients with unresectable pancreatic 
cancer include chemotherapy, radiation therapy, 
preoperative neoadjuvant combined chemotherapy and 
radiation therapy (CCRT), postoperative adjuvant CCRT, 
etc. In the recent years, many institutions have been 
using CCRT for resectable or unresectable locally invasive 
pancreatic cancers because it has been reported to improve 
the local recurrence and survival rates (16, 17). However, 
CCRT cannot be persistently used because it is restricted by 
the total radiation dose. Therefore, after CCRT is fi  nished, 
chemotherapy is only available treatment option in the 
current treatment scheme. On the other hand, CCHT can be 
persistently repeated because its use is not limited by the 
total dose. Therefore, if CCHT is clinically proven to be an 
effective modality for the treatment of pancreatic cancer 
by a well-designed study, then it can be used anytime in 
conjunction with the current treatment schemes to more 
improve the survival rates.   
In the present study, two of the three patients in the 
CCHT group achieved survival times of 26.0 months and 
21.6 months with an excellent physical condition and no 
major complications. The other patient also maintained a 
good physical condition for 11 months from the time of 
diagnosis without any signifi  cant increase in tumor size or Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 185
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de novo distant metastasis. 
A recent clinical study was undertaken to examine 
concurrent gemcitabine and HIFU therapy in patients with 
locally advanced pancreatic cancer (13). In that previous 
study, the median OS was 12.6 months (95% CI: 10.2-15.0 
months), which was an excellent result compared to the 
previous studies on chemotherapy alone (3, 4, 6), combined 
chemotherapy and radiotherapy (5) or HIFU therapy alone 
(2). That previous study excluded the cases of unresectable 
pancreatic cancer with metastatic disease. In our study, 
two patients in the CCHT group survived for longer than the 
upper limit of the 95% CI of the previous CCHT study, even 
though one of the two had liver metastasis. Furthermore, 
these two patients were still alive at the time of preparing 
this manuscript and they were in a near normal physical 
condition. The major difference between the CCHT protocols 
of the present and previous CCHT studies was the time 
interval between gemcitabine administration and the HIFU 
treatment. In the previous study, the patients received 
gemcitabine on days 1, 8 and 15 and HIFU therapy on days 
1, 3 and 5. In other words, concurrent use of gemcitabine 
and HIFU was performed in the same day once per month. 
In contrast, the patients in our study received HIFU within 
24 hours of gemcitabine administration in every CCHT. 
According to our TTP, the CA 19-9 level and the CT 
fi  ndings, the period of growth inhibition appeared to 
extend beyond eight months from the time of initiating 
administering chemotherapeutic agents in all three patients, 
which, in our opinion, contributed to their excellent survival 
times. In several animal studies, CCHT induced apoptosis 
and it inhibited tumor growth more than chemotherapy or 
HIFU alone (10-12, 18). The mechanistic rationale for the 
inhibition of tumor growth by CCHT is based on the thermal 
and non-thermal effects of pulsed HIFU. Thermally, the 
pulsed HIFU induces an increase in blood fl  ow to the target 
tissues by causing local hyperthermia, which increases 
drug delivery, and it also mechanically induces structural 
and molecular changes at the cellular and molecular levels 
due to acoustic cavitation, radiation force, shear stress 
and acoustic streaming/microstreaming, which all might 
enhance drug extravasation and sensitize the cancer cells 
to chemotherapeutic agents (1, 11).
The median OS and TTP of our non-CCHT group are similar 
to the results of the previous studies, with considering 
that the median OSs and median TTPs of gemcitabine 
and gemcitabine-capecitabine chemotherapies are 6-10 
months and 3.8-5.4 months, respectively, for patients with 
advanced pancreatic cancer (3-6).
In terms of safety, no major complications, other than 
one event of pancreatitis, was encountered in either study 
group. However, mild pain was not uncommon during 
treatment, but it was well controlled with analgesics. When 
energy of 900-1000 J/spot was initially administered at 
our center, four patients presented with severe abdominal 
pain during the HIFU treatment and another two patients 
experienced a subcutaneous burn. However, no severe 
pain or subcutaneous burn has been encountered during 
treatment since this dose was reduced to 800 J/spot or less. 
Given that all three patients in the CCHT group received a 
mean target energy/spot of less than 850 J, a target energy 
of less than 800 J/spot might well be advisable. 
HIFU carries a risk of biliary perforation or biliary duct 
damage by thermal injury when cancers are located in the 
head of the pancreas. To reduce the risk, a previous study 
recommended placing a biliary stent before HIFU in patients 
with cancer in the pancreatic head (2). In this current 
study, two patients with invasion of the distal common bile 
duct in the CCHT group underwent metallic biliary stent 
insertion due to obstructive jaundice before the initiation 
of CCHT. The biliary stents were always included in the 
treatment territory in all the HIFU sessions, and there was 
no evidence of a biliary obstruction or leakage in both 
patients. This suggests that metallic stents can prevent 
biliary complications. In addition, stents have the potential 
to augment the ablation of tumors around the stents 
by refl  ecting the HIFU beam, yet further study will be 
needed to validate this issue. Until the safety is validated, 
HIFU should be performed very carefully in patients with 
pancreatic head cancers, even though a metallic stent is 
inserted, because HIFU is potentially harmful to the bile 
ducts. 
The present study had several limitations. First, the 
number of cases was small and the study was limited by 
its retrospective design. Applying an intention-to-treat 
principle revealed a technical success rate for CCHT of 
25% (3 of 12 patients). However, this study highlighted 
the potential of CCHT using a practical treatment protocol 
prior to conducting any well-controlled prospective study. 
Second, a selection bias could not be avoided because 
the CCHT group consisted of patients with an excellent 
Karnofsky performance status at the time of the initial 
treatment, and a good performance status has a signifi  cant 
effect on the survival of patients with pancreatic cancer (4). 
Nevertheless, the survivals achieved by the three patients Korean J Radiol 12(2), Mar/Apr 2011 www.kjronline.org 186
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in the CCHT group were remarkable. These fi  ndings appear 
to justify conducting a well-designed prospective study to 
prove the value of CCHT in a more rigorous manner. Third, 
this study was also limited by its empirical nature in terms 
of determining the timing and CCHT doses, even though the 
acoustic intensity used in the study was based on that used 
in a previous study (15). Therefore, its validity should be 
confi  rmed in a further study. 
In conclusion, CCHT has excellent potential to become 
an effective and safe modality for treating unresectable 
pancreatic cancer. 
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